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Increased levels of exhaled nitric oxide (FeNO) and airway hyperresponsiveness (AHR) to
inhaled mannitol are related to allergic inflammation characterized by eosinophil infiltration
and a clinical response to treatment with anti-inflammatory agents in subjects with asthma.
This study determines the diagnostic accuracy of FeNO using absolute and normalized values
to predict the presence of AHR to inhaled mannitol in an unselected population.
Levels of FeNO and AHR to inhaled, dry-powder mannitol was measured in 180 unselected,
steroid-naı¨ve, non-smoking adolescents and young adults.
The area under the curve for the receiver operating characteristics curve for FeNO to iden-
tify a positive response to mannitol was 91.9% (CI95: 87.7e96.2). The optimal cut-off was
25 ppb (185% predicted) and a sensitivity of 100% (CI95: 83.9e100.0) was achieved below
20 ppb (165% predicted).
FeNO is a sensitive and specific tool for predicting the response to inhaled mannitol in an
unselected sample of non-smoking, steroid-naı¨ve subjects, and a low FeNO indicates that extra
diagnostic work-up using inhaled mannitol will add very little extra information.
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Figure 1 ROC curves for FeNO absolute values (black circles)
and FeNO% predicted values (gray diamonds) to predict AHR to
mannitol in non-smoking, steroid-naı¨ve subjects (n Z 180).
Predicting airway hyperreactivity to mannitol 151Chronic inflammation of the airways and airway hyper-
responsiveness (AHR) are two key pathological features of
asthma. The fraction of exhaled nitric oxide (FeNO) is
considered an easy and non-invasive marker of airway
inflammation. Increased levels of FeNO are closely related
to allergic inflammation characterized by eosinophil infil-
tration and a clinical response to treatment with anti-
inflammatory agents such as inhaled corticosteroids (ICS).1
Inhaled mannitol, a standardized test for AHR2 with a high
diagnostic specificity for asthma,3 is also suggestive of
active inflammation of the airways that will benefit from
regular anti-inflammatory treatment. In a selected group of
subjects with asthma, raised levels of FeNO correlate with
responsiveness to mannitol,4 and the findings were similar
in an unselected group.5 Both FeNO and mannitol are used
regularly as diagnostic tools in the assessment of asthma,
and we expect a significant overlap in the properties of the
two tests.
The aim of this study was to analyze to what extent
FeNO can be used to predict AHR to mannitol, considering
that FeNO measurement is easier to perform than mannitol
challenge. Furthermore, the diagnostic accuracy of abso-
lute and normalized FeNO in predicting the AHR to inhaled
mannitol (% predicted using published reference equations)
was compared.
The study is a post hoc analysis on prior published data3,5
on subjects randomly drawn from the civil registration list
(n Z 238) aged 14e24 years (median 19) who had their
FeNO (median 15.0 ppb, range 4e263 ppb), lung function
and reactivity to mannitol measured. Skin prick tests were
performed for the most common aeroallergens.5 Data on
smoking status (51 subjects were current smokers), use of
medication (8 were currently on ICS) and respiratory
symptoms were obtained through an interview at the time
of examination. FeNO levels were measured online (NIOX;
Aerocrine AB, Solna, Sweden), according to ATS/ERS
recommendations.6 AHR to mannitol was defined as
a decrease in forced expiratory volume in one second
(FEV1) of at least 15% after inhalation of 635 mg of mannitol
or less. Further details about the methods are available in
earlier publications.3,5
STATA12.0 (StataCorp, TX,USA)wasused for theanalysis.
A receiver operating characteristic (ROC) curve was con-
structed by plotting levels of FeNO (both absolute and
normalized) against a positive mannitol challenge. The area
under the curve (AUC) and the optimal FeNO cut-off (defined
as the cut-off atwhich sensitivity and specificitywere closest
together) were calculated. Normalized levels of FeNO were
obtained by using a reference equation based on height from
Malmberg et al. and extrapolating to 24 years.7 The age
effect was considered negligible in this sample.
Of 238 subjects included (142 women), 51 were classi-
fied as having asthma (based on the assessment of a respi-
ratory specialist blinded to the result of AHR to inhaled
mannitol3), 76 had allergic rhinitis and 33 had a positive
mannitol test (PD15  635 mg). Non-atopic, non-smoking,
non-asthmatic subjects with no current use of ICS (nZ 104)
had a mean FeNO% predicted (95%CI) of 101.9 (93.1, 111.6).
AUC for absolute values of FeNO was 89.6% (CI95:
84.0e95.2), which means that a subject with a positive
mannitol challenge has a 90% probability of having a higher
level of FeNO than a subject with a negative mannitolchallenge. Using normalized instead of absolute FeNO
values increased AUC to 90.6% (CI95: 85.4e95.8),
p Z 0.046. When current smokers and/or subjects on ICS
were excluded, 180 subjects remained and were included in
the final analysis. The subgroup of 180 subjects did not
differ from the original 238 subjects in terms of sex or
atopic status, but the mean age (years) was lower (18.6 vs
18.9, p < 0.01) and fewer had asthma (16.1% vs 21.4,
p < 0.01). In the subgroup, there was no significant
difference between absolute and normalized FeNO values,
AUC being 91.9% (CI95: 87.7e96.2) and 92.4% (CI95: 88.4,
96.4), respectively (Fig. 1). Diagnostic accuracy of FeNO
when compared against a positive mannitol challenge test
in this subgroup is presented in Table 1.
The results indicate that FeNO is a both sensitive and
specific tool for predicting AHR to mannitol in an unse-
lected population of steroid-naı¨ve subjects. The optimal
cut-off was 25 ppb (185% predicted). At 20 ppb (165% pre-
dicted) the sensitivity was 100% with only a minor
concomitant reduction in specificity, implying that at
20 ppb or below AHR to mannitol is very unlikely. The cut-
off resembles the recently published American Thoracic
Society clinical guidelines on use of exhaled NO suggesting
that the presence of eosinophilic airway inflammation is
unlikely below 25 ppb.8 A cut-off of 30 ppb (210% pre-
dicted), on the other hand, resulted in a specificity of 90%,
which indicates that nine out of ten subjects without AHR
to mannitol will present with a FeNO below 30 ppb. At
higher values of FeNO, specificity was further increased but
with a marked reduction in sensitivity.
Two of the original 238 subjects had a FeNO below
20 ppb and were also responsive to mannitol, but were
excluded from analysis due to their status as current
smokers, as smoking is associated with reduced FeNO and
increased AHR to mannitol. Levels of FeNO and reactivity to
mannitol are both decreased during ICS treatment.
Excluding subjects that used ICS in our sample did not
change the AUC significantly. However, the sample con-
tained few subjects on ICS treatment, and hence we cannot
draw conclusions about the usefulness of FeNO for pre-
dicting AHR to mannitol in ICS-treated subjects with
asthma.
Table 1 Predictive values of FeNO (absolute values in Panel A and % predicted values in Panel B) at three cut-offs (100%
sensitivity, optimal cut-off, 90% specificity) in non-smoking, steroid-naı¨ve subjects 14e24 years old (n Z 180).
Sensitivity (95%CI) Specificity (95%CI)
A. FeNO absolute 20 ppb 1.000 (0.839e1.000) 0.748 (0.674e0.814)
25 ppba 0.857 (0.637e0.970) 0.836 (0.770e0.890)
30 ppb 0.714 (0.478e0.887) 0.906 (0.849e0.946)
B. FeNO% predicted 165% 1.000 (0.839e1.000) 0.818 (0.749e0.874)
185%a 0.857 (0.637e0.970) 0.836 (0.770e0.890)
211% 0.714 (0.478e0.887) 0.906 (0.849e0.946)
a Optimal cut-off corresponding to where sensitivity and specificity are closest together.
152 A. Sverrild et al.In our subject sample, highly homogenous e.g. in terms
of ethnicity and age, diagnostic accuracy was only mini-
mally improved by using normalized instead of absolute
FeNO values. However, cut-offs expressed in % predicted
are readily generalized, enabling them to be applied to
other groups of patients, for example children.
In conclusion, FeNO is a sensitive and specific tool for
predicting the response to inhaled mannitol in an unse-
lected sample of non-smoking, steroid-naı¨ve subjects. At
a FeNO value below 20 ppb (or approximately 165% pre-
dicted) the sensitivity (and negative predictive value) is
100%, which implies that AHR to mannitol can be ruled out
with great certainty and that extra diagnostic work-up
using inhaled mannitol will add very little extra informa-
tion. The diagnostic value of FeNO should be further
explored in symptomatic subjects with suspected asthma in
order to see whether the result of a low FeNO also excludes
AHR to mannitol in this group of subjects, and to be able to
define clinically relevant predictive values for a diagnosis of
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